Bridging the Gaps in PARP Inhibitor Use for Metastatic Prostate Cancer in the Healthcare System - CME

CME

Title: Bridging the Gaps in PARP Inhibitor Use for Metastatic Prostate Cancer in the Healthcare System

Description: This program will prepare clinicians with a comprehensive understanding of the appropriate treatment of patients with mPC and the clinical utility of agents that could significantly impact patient outcomes. PARPis, which are one of the most promising new classes of agents for mPC, offer the potential for better survival, but clinicians require education to address the challenges of integrating these agents into practice. This program will review the latest evidence on genetic testing to guide treatment selection, other methods for personalizing therapy, the indications for PARP inhibitor-based monotherapy and combination therapy for mPC, and how to manage safety concerns.

Target Audience: This activity is designed to meet the educational needs of Medical Oncologists, Urologists, Oncology Nurses, Pharmacists, NPs/PAs and other health care professionals who treat patients with prostate cancer

Learning Objectives

Assess the latest clinical trial data, guideline recommendations, and expert opinions on the use of PARP inhibitors for treating patients with mPC within the VHA.
Evaluate the evidence supporting biomarker-driven use of PARP inhibitors in mPC.
Identify and manage PARPi-related adverse events.
Formulate individualized treatment plans for veterans with mPC by integrating PARPis based on biomarker status, prior therapies, and comorbidities to optimize clinical outcomes and quality of life.

Disclosures and Disclaimers: The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, PleXus Communications, AstraZeneca and/or Merck Sharp & Dohme LLC. Authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	1 Credits	ACCME- Accreditation Council for Continuing Medical Education
Nursing	1 Contact Hours	ANCC - American Nurses Credentialing Center
Pharmacy	1 Contact Hours	ACPE- Accreditation Council for Pharmacy Education